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Abstract 
Background: We performed a meta‑analysis of randomized controlled trials (RCTs) to determine if daily bathing with 
chlorhexidine decreased hospital‑acquired BSIs in critically ill patients.
Methods: We searched the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases to iden‑
tify randomized controlled trials that compared daily bathing with chlorhexidine and a control in critically ill patients.
Results: This meta‑analysis included five RCTs. The overall incidence of measured hospital‑acquired BSIs was sig‑
nificantly lower in the chlorhexidine group compared to the controls 0.69 (95 % CI 0.55–0.85; P < 0.001; I2 = 57.7 %). 
Gram‑positive‑induced (RR = 0.49, 95 % CI 0.41–0.58; P = 0.000; I2 = 0.0 %) bacteremias were significantly less 
common in the chlorhexidine group. The incidence of MRSA bacteremias (RR 0.63; 95 % CI 0.44–0.91; P = 0.006; 
I2 = 30.3 %) was significantly lower among patients who received mupirocin in addition to chlorhexidine bathing 
than among those who did not routinely receive mupirocin.
Conclusions: Daily bathing with chlorhexidine may be effective to reduce the incidence of hospital‑acquired BSIs. 
However, chlorhexidine bathing alone may be of limited utility in reduction of MRSA bacteremia; intranasal mupirocin 
may also be required. This meta‑analysis has several limitations. Future large‑scale international multicenter studies 
are needed.
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Background
Up to 20–30  % of patients admitted to intensive care 
units (ICUs) develop a hospital-acquired infection during 
their ICU stay [1]. Many of these infections are caused 
by multidrug-resistant organisms, such as methicillin-
resistant Staphylococcus aureus (MRSA) and vancomy-
cin-resistant Enterococcus (VRE), limiting the number of 
antibiotics available for treatment. These infections pro-
long the length of stay and increase the costs of care and 
patient morbidity and mortality [2, 3]. Center for Disease 
Control and Prevention (CDC) recommends hand wash-
ing and isolation for precautions, but these strategies are 
not easy to achieve the target. Because a lots of health-
care persons should be consistent adherence to strategies 
and continuously sustain [4].
Hospital-acquired infections are preceded by coloni-
zation with pathogenic bacteria, and hospital-acquired 
bloodstream infections (BSIs) often result from the 
ingress of skin organisms into the bloodstream along 
vascular catheters or other breaks in skin integrity [5]. 
Successful efforts to decolonize patients have reduced 
the rates of these infections. Chlorhexidine is a water-
soluble antiseptic preparation with broad activity against 
Gram-positive and Gram-negative organisms, facultative 
anaerobes, aerobes, and yeasts [6]. Recent investigations 
of whole-body skin decolonization with chlorhexidine 
in critically ill patients have demonstrated reductions in 
the rates of VRE, MRSA, and Acinetobacter baumannii 
colonization, and an overall decrease in the incidence of 
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central catheter-associated BSIs [7–10]. A previous meta-
analysis of non-randomized controlled trials (RCTs) 
suggested that the practice of daily bathing with chlo-
rhexidine decreased hospital-acquired BSIs [11]. Subse-
quently, some RCTs of daily bathing with chlorhexidine 
in the ICU have appeared [12–14].
Therefore, we conducted a meta-analysis of RCTs to 
determine whether daily bathing of critically ill patients 
with chlorhexidine decreases hospital-acquired BSIs 
compared to patients who received routine bathing.
Methods and statistics
The methods for including articles and analysis and 
reporting the results of meta-analyses are specified a pri-
ori in a protocol developed based on recommendations 
in the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement [15]. An ethics 
review of systematic reviews and meta-analysis studies, 
such as this study, was not required per our institutional 
Health Research Ethics Board.
Literature search strategy
We searched the databases of MEDLINE (1948 to August 
2014), EMBASE (1980 to August 2014), and the Cochrane 
Register of Controlled Trials (CENTRAL) of the Cochrane 
Library (Issue 8, 2014) using the search filter in the Ovid 
database (SIGN; http://www.sign.ac.uk). The search terms 
were “critical illness”, “intensive care units”, “burn units”, 
“coronary care units”, “respiratory care units”, “intensive 
care”, “ICU”, “infection control”, “universal precautions”, 
“decontamination”, “surveillance”, “screening”, “antisepsis”, 
“decolonization”, “chlorhexidine”, “Tubulicid”, and “Sebidin”. 
We also reviewed the bibliographies of relevant review 
articles to identify additional publications, and searched 
an international database (http://www.clinicaltrial.gov) to 
identify relevant ongoing or recently completed clinical 
trials. The search was performed without restriction with 
respect to language or year of publication. The last date on 
which a search was conducted was February 18, 2015.
Selection criteria for studies
Two authors (JP and EYC) independently evaluated the 
eligibility of all studies to determine whether they met 
each inclusion criterion. Disagreements between the 
two evaluators were resolved by discussion and consen-
sus, and with the opinion of a third reviewer (DAP). The 
eligibility criteria included all of the following: (a) study 
design, randomized controlled trials; (b) population, 
adult (>18 years old) critically ill patients in the ICU; (c) 
intervention, comparison between daily bathing with 
chlorhexidine and a control (daily bathing with soap and 
water or non-antimicrobial washcloths); and (d) out-
comes. The primary outcome was hospital-acquired BSIs, 
defined as bloodstream infections detected more than 
48 h after admission to the unit. The secondary outcomes 
were the types of reported microorganisms that caused 
hospital-acquired BSIs detected more than 48  h after 
admission to the unit and adverse effects of daily bathing 
with chlorhexidine. Studies that did not provide quantita-
tive data for the meta-analysis were excluded.
Data extraction and quality assessment
Two authors (JP and EYC) independently extracted the 
data using a standardized form. Only published data 
were used. The two extractors assessed the quality of the 
included trials using Cochrane Collaboration’s tool, and 
evaluated the risk of bias in randomized trials, which 
covers selection, performance, detection, attrition, and 
reporting bias [16]. High quality was defined as satisfy-
ing at least six of the seven criteria. We resolved disagree-
ments about data extraction and quality assessment by 
consensus or by discussion with a third reviewer (DAP).
Statistical analysis
The clinical outcomes in our analysis can be categorized 
as binary or continuous data. BSIs were quantified as 
patient-days. One patient-day represents a unit of time 
during which the services of the institution or facility are 
used by a patient. Relative risk (RR) and 95 % confidence 
interval (CI) were used as the summary effect for a binary 
outcome, and the standardized mean difference and 
95 % CI were used as the summary effect of a continuous 
outcome. Data were pooled using the Mantel–Haenszel 
method. We reported results according to a fixed-effects 
model in the absence of significant heterogeneity, and to 
a random-effects model [17] in the presence of signifi-
cant heterogeneity. We used the random-effects model 
because it accounts for variation among studies, in addi-
tion to sampling error within studies [16]. The appro-
priateness of pooling data across studies was assessed 
using Cochrane’s χ2 test and the I2 test for heterogeneity, 
which measure the inconsistency across the study results 
and describe the proportion of the total variation in the 
study estimates that is due to heterogeneity, rather than 
sampling error. Statistically significant heterogeneity was 
considered to be present when P < 0.10 and I2 > 50 % [18]. 
We checked the publication bias as subgroup analysis 
based on differences in design, type of control, the num-
ber of study sample, concomitant using drug, and so on. 
We followed the guidelines of the Cochrane Handbook 
for meta-analysis of randomized controlled studies, and 
PRISMA criteria were used to evaluate research meth-
odology (Fig. 1). Two-sided P values less than 0.05 were 
considered statistically significant. Meta-analyses, forest 
plots, and publication bias analyses were produced using 
Stata SE 13.1 for Mac (Stata Corp, TX, USA) [19]. We 
Page 3 of 9Choi et al. Ann. Intensive Care  (2015) 5:31 
pre-specified the subgroup analysis according to more 
similar interventions or control groups.
Results
Literature search and study selection
Figure 1 shows the flow diagram used for study selection. 
We identified 18,843 citations from electronic databases, 
and selected 34 potentially relevant publications for a full 
text assessment. Of these 34 articles, 30 were excluded 
from this meta-analysis for the following reasons: 18 tri-
als were not randomized controlled trials; 8 trials were 
only abstracts; and 3 trials [20–22] measured other out-
come variables. Two trials were duplicates; we included 
the most recent trial only [23]. Additionally, we found 
one study through hand searching under writing a manu-
script. Consequently, we included five studies in the final 
analysis [12–14, 24, 25].
Characteristics of the included studies
All of the trials were prospective, randomized trials, and 
three of them were crossover trials. One trial was post 
hoc analyzed after the completion of randomized control. 
The characteristics of the studies are presented in Table 1. 
Four studies used cloths impregnated with 2 % chlorhex-
idine (the equivalent of 500 mg chlorhexidine per cloth) 
(Sage Products) for decolonization, and a non-antiseptic 
Fig. 1 Flow‑diagram of the selection criteria. Flow chart explaining the selection of eligible studies included in the meta‑analysis
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liquid soap was applied as a comparator; and one trial 
compared 4  % chlorhexidine (Hibiscrub; AstraZeneca, 
Rueil-Malmaison, France) and non-antiseptic liquid soap. 
The study size ranged from 2210 to 10,603 patient-days. 
All of the studies examined adults. A funnel plot for pub-
lication bias could not be performed because there were 
too few trials to analyze with the Egger test.
Risk of bias in the included studies
Our assessments of each risk of bias item for each ran-
domized controlled study are summarized in Table  2. 
Three [12–14] of five trials were quasi-experimental, 
with limited to no assessment of potential confounding 
factors. Four studies were cluster-randomized trials. We 
assessed these studies as being at low risk of allocation 
concealment. We assessed the study as being high risk of 
having a funding-related item when there were grants or 
support from a company. However, when public funding 
was used, we assessed the studies as low-risk.
Primary outcome: all‑cause hospital‑acquired BSIs
The primary outcome was the overall incidence of meas-
ured hospital-acquired BSI; 587 BSI events developed 
in the chlorhexidine group over 151,879 patient-days, 
compared to 670 in the control arm over 140,320 patient-
days. Fixed-effects modeling yielded an RR of 0.82 (95 % 
CI 0.73–0.91; P  <  0.001; I2 =  20.6  %). Figure  2 summa-
rizes the primary outcome.
Exploring the heterogeneity
Subgroup analyses of the potential effect of the concomi-
tant use of mupirocin were performed to determine the 
effects on measured and reported hospital-acquired BSI. 
Subgroup analysis at the results for hospital-acquired 
BSI was more homogeneous. Subgroup analysis featur-
ing the concomitant use of intranasal mupirocin yielded 
a pooled RR of 0.59 (95  % CI 0.51–0.68; P  <  0.001; 
I2  =  0.0  %). Subgroup analysis classified by the type of 
control group determined that the pooled RR was 0.68 
(95 % CI 0.55–0.85; P = 0.001; I2 = 0.0 %) between the 
groups washed with non-antimicrobial soap to treat 
hospital-acquired BSI. A subgroup analysis classified 
by the concentration of chlorhexidine revealed no sig-
nificant difference in hospital-acquired BSI. The pooled 
RR was 0.82 (95 % CI 0.73–0.92; P < 0.001; I2 = 32.5 %) 
between 2  % chlorhexidine groups. The pooled RR for 
reported hospital-acquired BSI was 0.82 (95 % CI 0.73–
0.92; P < 0.001; I2 = 32.5 %) when a study performed as 
post hoc analysis in the 1990s was excluded. The pooled 
RR for reported hospital-acquired BSI was 0.77 (95 % CI 
0.65–0.91; P =  0.002; I2 =  27.1 %) when a largest study 
was excluded.
Of all hospital-acquired BSIs, central catheter-related 
BSIs were defined as BSIs noted in patients for whom at 
least one central venous catheter was placed within 48 h 
before detection of the infection. Two studies presented 
quantitative data [12, 14]; 30 central catheter-related BSI 
events developed in the chlorhexidine group over 14,824 
catheter-days, compared to 65 in the control arm over 
14,297 catheter-days. Fixed-effects modeling yielded an 
RR of 0.44 (95 % CI 0.28–0.67; P < 0.001; I2 = 0.0 %).
Secondary outcomes
Microorganisms were isolated from bloodstream infections
In total, 475 microorganisms for 132,678 patient-days 
in the chlorhexidine group and 543 microorganisms for 
119,600 patient-days in the control group were isolated in 
BSIs (RR 0.73, 95 % CI 0.57–0.93; P = 0.001, I2 = 51.1 %).
Four of the five trials in this meta-analysis reported 
the isolation of Gram-positive pathogens. Overall BSIs 
caused by Gram-positive pathogens involved 251 events 
in 132,678 patient-days with chlorhexidine compared 
to 351 events for 119,600 patient-days in the controls. 
Figure  3 summarizes the Gram-positive pathogens iso-
lated. The summary effect of Gram-positive pathogens 
had a pooled RR of 0.59 (95 % CI 0.44–0.79; P  < 0.001; 
I2 = 46.0 %) in a random-effects model. Subgroup analy-
sis yielded more homogeneous results for Gram-positive 
pathogen-related BSIs. Subgroup analysis of mupirocin 
use in conjunction with chlorhexidine bathing yielded 
Table 2 Risk of bias assessment for the randomized controlled studies included in this meta-analysis
Study Bleasdale et al. [24] Climo et al. [12] Huang et al. [13] Camus et al. [25] Noto et al. [16]
Adequate sequence generation? Low Unclear Low Unclear Low
Allocation concealment? Low Low Low Low Low
Blinding of participants and personnel? High High Unclear Low High
Blinding of outcome assessment? Low High Low Low Low
Incomplete outcome data addressed? Low Low Low Low Low
Free of selective reporting? Low Low Low Low Low
Free of potential bias relevant industrial funding? High High Low High Low
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a pooled RR of 0.69 (95  % CI 0.57–0.83; P  =  0.001; 
I2 = 21.6 %). There were significantly fewer MRSA-related 
BSIs with chlorhexidine than in the controls (pooled RR 
0.64; 95  % CI 0.47–0.88; P =  0.006; I2 =  0.0  %; Fig.  4). 
In subgroup analysis by mupirocin use, MRSA-related 
BSIs were significantly fewer in the group featuring con-
comitant use of intranasal mupirocin and chlorhexidine 
bathing the chlorhexidine bathing compared to chlorhex-
idine bathing alone (pooled RR 0.63; 95 % CI 0.44–0.91; 
P = 0.013; I2 = 30.0 %).
Three of the five trials indicated the isolation of Gram-
negative pathogens. The infections caused by Gram-neg-
ative pathogens involved 132 of 32,204 patient-days with 
chlorhexidine compared to 111 of 29,441 patient-days 
in the controls. The summary effect of Gram-negative 
pathogens was a pooled RR of 1.09 (95 % CI 0.85–1.40; 
P = 0.51; I2 = 0.00 %) in the fixed-effects model.
Three of the five trials isolated fungal pathogens. There 
were 73 fungal infections for 32,204 patient-days with 
chlorhexidine compared to 70 for 29,441 patient-days 
in the controls. The summary effect of fungal infection 
was a pooled RR of 0.83 (95  % CI 0.42–1.62; P =  0.56; 
I2 = 52.1 %) in the random-effects model.
Adverse effects: skin rash
Four of the five studies included in this meta-analysis 
reported chlorhexidine-related skin rashes as an adverse 
effect of chlorhexidine. In total, 92 events in the chlo-
rhexidine group developed over 132,678 patient-days 
compared to 136 events in the control arm over 119,600 
patient-days. A random-effects model resulted in an RR 
of 1.20 (95 % CI 0.43–3.31; P = 0.73; I2 = 56.3 %).
Discussion
In this meta-analysis of five randomized controlled tri-
als, we found that daily bathing with chlorhexidine 
reduced the development of hospital-acquired BSIs more 
effectively with the concomitant use of intranasal mupi-
rocin. BSIs caused by Gram-positive cocci in critically 
ill patients also decreased significantly. However, chlo-
rhexidine bathing had a limited effect on reducing BSIs 
caused by MRSA. MRSA-BSIs were significantly fewer 
Fig. 2 The overall incidence of hospital‑acquired bloodstream infections. Each effect size is shown with its confidence interval (CI) as solid triangle. 
The overall effect and CI are shown as a diamond with a dotted line indicating its location. Vertical solid line at 1 indicates no treatment effect. M–H 
Mantel–Haenszel weighted fixed effects, D + L random‑effects estimate
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in only subgroups in the concomitant use of intranasal 
mupirocin. And, chlorhexidine bathing would be helpful 
to reduce the incidence of Gram-negative bacteremia and 
fungemia. The overall incidence of adverse events such as 
skin rashes was similar between daily bathing with chlo-
rhexidine and the control.
Our data were consistent with those in the meta-analysis 
reported by O’Horo et  al. [11] or Derde et  al. [26] which 
indicated efficacy of daily bathing with chlorhexidine in 
order to decrease hospital-acquired BSIs. O’Horo et  al. 
included only 1 RCT [24] and 11 observational studies. 
They pooled the studies together regardless of study design. 
We included five RCTs and removed observational trials. 
As the previous report, chlorhexidine bathing reduced the 
development of hospital-acquired BSIs caused by Gram-
positive cocci. In recent evidence [11, 26] (not from RCTs) 
also reported that chlorhexidine bathing effectively pre-
vented MRSA BSIs in critically ill patients. These studies 
did not distinguish whether effects came from chlorhex-
idine alone or combination of mupirocin and chlorhexidine. 
Our results showed some limitations about chlorhexidine 
bathing alone. In enrolled studies in our meta-analysis, the 
combination group had studies with higher quality and 
larger than chlorhexidine alone group. One study in com-
bination group completed more than 15 years ago (1996–
1999), several practices that may impact catheter-related 
BSIs have changed significantly during those years. Pre-
vention of MRSA seems to require a combination of chlo-
rhexidine and mupirocin. In our results, daily bathing with 
chlorhexidine did not affect BSI caused by Gram-negative 
bacteria or fungi. This may be because Gram-negative BSIs 
often originate from the lung or digestive tract, and are 
therefore not impacted by the chlorhexidine skin wash.
Our meta-analysis had some limitations. First, it 
involved a small number of studies, and the five RCTs in 
this meta-analysis had various study designs: one of five 
trials was a 2 × 2 factorial design [25] with other interven-
tions (topical polymyxin and tobramycin) and post hoc 
analysis. Three trials [12–14] of five trials were crossover 
or cluster random designs. It may be considerably smaller 
number of RCT studies when it is assumed that a clus-
ter enrollment. Infection rates are different in each ICU. 
The infection related interventions could be affected by 
the infection state neighbor patients. Maybe even given 
these limitations are infection-related design seems to be 
a cluster randomized controlled trials possess a greater 
Fig. 3 Gram‑positive bacteria isolated from bloodstream infections. Each effect size is shown with its confidence interval (CI) as solid triangle. The 
overall effect and CI are shown as a diamond with a dotted line indicating its location. Vertical solid line at 1 indicates no treatment effect. M–H Man‑
tel–Haenszel weighted fixed effects, D + L random‑effects estimate
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advantage. We tried to overcome these limitations accord-
ing to various study design with multiple sensitivity-test. 
However, our results were continuously constant.
Second, most of the studies enrolled in this meta-anal-
ysis were not high quality due to the open-label study 
design. Additionally, three of the five studies could not 
guarantee blinded studies. The studies for infection were 
strikingly influenced by adherence to infection control. 
It was possible to overestimate the intervention effects. 
Therefore, caution is needed when interpreting the 
results. Third, the microorganisms reported were very 
different. One study [25] reported only S. aureus blood-
stream infections. For fungi, two studies [13, 24] reported 
only Candida, one study [12] reported Candida and oth-
ers, and the other did not report fungi. The results for 
Gram-negative bacteria came from three of the five tri-
als. This might contribute to a lack of confidence in the 
results. Fourth, none of studies reported the baseline 
patient characteristics. We only estimated the similarity 
between studies or groups based on a low I2 value. Fifth, 
one [25] of the five studies used 4  % Hibiscrub® soap 
instead of 2 % chlorhexidine cloths. The chlorhexidine of 
the soap might have been diluted; lower concentrations 
of chlorhexidine exert bacteriostatic effects, thus being 
less effective than chlorhexidine-impregnated cloth bath. 
To overcome this problem, we performed a subgroup 
analysis by chlorhexidine concentration, and found no 
significant difference in hospital-acquired BSIs, including 
those caused by Gram-positive bacteria or MRSA. Sixth, 
four of the five studies were performed in the United 
States and the other was performed in France; thus, the 
regional environment in the United States could have 
affected these results. A multinational RCT on this topic 
is necessary to overcome these limitations.
In conclusion, daily bathing with chlorhexidine was 
associated with reductions in the rates of measured hos-
pital-acquired BSI without significant complications in 
critically ill patients. Daily bathing with chlorhexidine 
decreased the incidence of Gram-positive bacteremia 
regardless of mupirocin use. However, chlorhexidine-
only bathing may not be entirely effective to decrease 
MRSA-related hospital-acquired BSIs. We should con-
sider to emergence of resistance when daily chlorhex-
idine bathing in the ICUs was implemented [27]. Further 
Fig. 4 Methicillin resistant S. aureus isolated from bloodstream infections. Each effect size is shown with its confidence interval (CI) as solid triangle. 
The overall effect and CI are shown as a diamond with a dotted line indicating its location. Vertical solid line at 1 indicates no treatment effect. M–H 
Mantel–Haenszel weighted fixed effects, D + L random‑effects estimate
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multinational, multicenter RCTs are required to over-
come the limitations of the meta-analysis.
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Take Home message 
Daily bathing with chlorhexidine may be effective to reduce the incidence of 
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blinding bias.
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